Program
prasinezumab
Also written as “Prasinezumab”, “RO7046015” and “PRX002”.
Its studies are mostly in Parkinson Disease, led by 2 companies.
Furthest: phase 3, since Sep 12, 20255 company-led studies, 3 open or runningNext primary completion: Jun 30, 2029 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 33 open or running | phase 3since Sep 12, 2025 | Mar 29, 2017 | Jun 30, 2029phase 3 · NCT07174310 |
| Prothena Biosciences | 20 open or running | phase 1since Mar 14, 2014 | Mar 14, 2014 | none ahead |
- Named in Hoffmann-La Roche’s own pipeline as
RG7935 prasinezumab
, phase 3, as of Oct 22, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 14, 2014First study: phase 1 study in Parkinson DiseaseNew to Prothena BiosciencesProthena Biosciences · NCT02095171 · 40 enrolled · United States
- Jun 4, 2014Phase 1 study in Parkinson DiseaseProthena Biosciences · NCT02157714 · 64 enrolled · United States
- Mar 29, 2017Hoffmann-La Roche's first study: phase 2 study in Parkinson DiseaseNew to Hoffmann-La RocheHoffmann-La Roche · NCT03100149 · 316 enrolled · United States, Austria, France and more
- Feb 26, 2021Phase 2 study in Parkinson DiseaseHoffmann-La Roche · NCT04777331 · 586 enrolled · United States, Austria, Canada and more
- Sep 12, 2025Phase 3 study in Parkinson DiseaseHoffmann-La Roche · NCT07174310 · 900 planned · United States, Australia, Austria and more
Ahead
- Jun 30, 2029Primary completion: phase 3 study in Parkinson DiseaseHoffmann-La Roche · NCT07174310
TargetBeta
SNCA →read by rule
“Alpha-synuclein binding agent”ChEMBL 37, by rule
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07174310Parkinson Disease · United States, Australia, Austria and more | 3 | Recruiting | Hoffmann-La Roche | Jun 30, 2029 | 900 |
| NCT04777331Parkinson Disease · United States, Austria, Canada and more | 2 | Active, not recruiting | Hoffmann-La Roche | Sep 11, 2024 | 586 |
| NCT03100149Parkinson Disease · United States, Austria, France and more | 2 | Active, not recruiting | Hoffmann-La Roche | Nov 27, 2019 | 316 |
| NCT02157714Parkinson Disease · United States | 1 | Completed | Prothena Biosciences | Sep 2016 | 64 |
| NCT02095171Parkinson Disease · United States | 1 | Completed | Prothena Biosciences | Dec 2014 | 40 |
How it is read
Names in the registry
- “Prasinezumab”, 2 entries
- “RO7046015”, 2 entries
- “PRX002”, 2 entries
Conditions, from the studies’ own filings
- Parkinson Disease, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.